Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen‐season model of allergic rhinitis

@article{AhlstrmEmanuelsson2004TopicalTW,
  title={Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen‐season model of allergic rhinitis},
  author={Cecilia Ahlstr{\"o}m-Emanuelsson and M. Andersson and Carl Persson and Camilla Schrewelius and Lennart Greiff},
  journal={Clinical \& Experimental Allergy},
  year={2004},
  volume={34}
}
Background Rofleponide palmitate is an esterified glucocorticosteroid pro‐drug with a promising pre‐clinical profile designed to deliver topical airway treatment for allergic rhinitis and asthma in a novel manner. Thus, the rofleponide palmitate pro‐drug is designed to provide topical exposure of the mucosa to the inactive lipophilic drug, which would be locally metabolized to the more hydrophilic and readily cleared drug rofleponide. 
Investigational drugs for the treatment of allergic rhinitis
TLDR
It is the opinion that despite developments in new therapies, a multidrug approach is vital for successful treatment of allergic rhinitis and immunotherapy in the form of sublingual immunotherapy is a promising additional therapeutic approach that will potentially make immunotherapy available to a wider selection of eligible patients.
Clinical efficacy and pharmacokinetic profiles of intranasal and oral cetirizine in a repeated allergen challenge model of allergic rhinitis.
  • M. Korsgren, M. Andersson, L. Greiff
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2007
New Therapies for Allergic Rhinitis
TLDR
The aim of this review is to provide an update on allergic rhinitis treatment, paying particular attention to clinical trials published within the past 20 months that assessed the efficacy and safety of new formulations of available drugs or new molecules.
Emerging drugs for perennial allergic rhinitis
TLDR
In the last years there have been very few innovative approaches to optimize the management of AR, and some more promising advances have been shown for allergen immunotherapy, where a number of new strategies are currently under development.
Investigational drugs for allergic rhinitis
TLDR
Attempts are currently made to improve the existing molecules and to develop new drugs, in order to achieve greater clinical efficacy with a better tolerability of allergic rhinitis.
Novel, Alternative, and Controversial Therapies of Rhinitis.
Does Lipophilicity Per Se Induce Adjuvant Effects? Methyl Palmitate as Model Substance Does Not Affect Ovalbumin Sensitization
TLDR
Results showed that effects of adjuvants not are necessarily due to their lipophilicity; that is, additional structural properties are required.
Allergic rhinitis: current options and future perspectives
TLDR
Available and new drugs under investigation seem able to control rhinitis symptoms without a significant patient's burden, and the challenge for the next years will be to improve treatment adherence rather than to introduce new drugs.
Emerging drugs for the treatment of perennial allergic rhinitis
TLDR
The ultimate research goal is beyond symptomatic treatment, and is mainly directed at modifying the immune response to allergens and prevent the progression of allergic rhinitis towards asthma.
...
1
2
3
...

References

SHOWING 1-10 OF 14 REFERENCES
Mucosal output of eotaxin in allergic rhinitis and its attenuation by topical glucocorticosteroid treatment
  • L. Greiff, H. Petersen, C. Persson
  • Medicine
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2001
TLDR
The occurrence of eotaxin in nasal mucosal surface liquids in patients with seasonal allergic rhinitis without allergen exposure and during repeat allergenic challenge with and without topical glucocorticosteroid treatment is examined.
Glucocorticosteroids and rhinitis
TLDR
This paper reviews the literature, and presents 20 years' clinical experience of topical GCS treatment for rhinitis, and describes the pathophysiology of the disease and the putative modes of action of GCSs in the nose.
Clinical and antiinflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis.
  • E. Meltzer
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 1998
Dose-dependent effects of budesonide aqueous nasal spray on symptoms in a daily nasal allergen challenge model.
Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis.
  • E. Bronsky, D. Aaronson, K. Nolop
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 1997
Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid.
A Comparison of Aqueous Suspensions of Budesonide Nasal Spray (128 μg and 256 μg Once Daily) and Fluticasone Propionate Nasal Spray (200 μg Once Daily) in the Treatment of Adult Patients with Seasonal Allergic Rhinitis
TLDR
Analysis of symptom scores on days when the pollen count was greater than 10 grains/m3 revealed 256 μg/day of budesonide therapy to be significantly more effective in reducing combined symptom scores as well as the individual scores for sneezing and runny nose, compared with 200 μg/ day fluticasone propionate.
A comparison of the efficacy and safety of inhaled corticosteroids in asthma
TLDR
The high safety margin of inhaled therapy with GCSs has encouraged an increasingly widespread use of these compounds in patients with moderate to severe asthma over the past 20 years, and especially where high firstpass metabolism to inactive compounds in the liver has been demonstrated.
Allergen-induced eosinophil cytolysis is a primary mechanism for granule protein release in human upper airways.
TLDR
The nature and extent of the ECL and its product indicate that allergen-induced cytolysis is a primary and major mechanism for the release of eosinophil proteins in human allergic airway inflammation in vivo.
...
1
2
...